Nuvation Bio Inc (NYSE: NUVB) kicked off on Thursday, up 4.79% from the previous trading day, before settling in for the closing price of $1.88. Over the past 52 weeks, NUVB has traded in a range of $1.54-$3.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 73.12%. With a float of $226.88 million, this company’s outstanding shares have now reached $336.84 million.
Let’s determine the extent of company efficiency that accounts for 220 employees. In terms of profitability, gross margin is 6.26%, operating margin of -2128.25%, and the pretax margin is -7213.76%.
Nuvation Bio Inc (NUVB) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nuvation Bio Inc is 33.21%, while institutional ownership is 45.59%. The most recent insider transaction that took place on Apr 07 ’25, was worth 487,500. In this transaction PRESIDENT AND CEO of this company bought 300,000 shares at a rate of $1.62, taking the stock ownership to the 58,781,054 shares. Before that another transaction happened on Apr 04 ’25, when Company’s PRESIDENT AND CEO bought 200,000 for $1.66, making the entire transaction worth $332,720. This insider now owns 58,481,054 shares in total.
Nuvation Bio Inc (NUVB) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 73.12% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.20% during the next five years compared to -49.14% drop over the previous five years of trading.
Nuvation Bio Inc (NYSE: NUVB) Trading Performance Indicators
Take a look at Nuvation Bio Inc’s (NUVB) current performance indicators. Last quarter, stock had a quick ratio of 9.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 85.03.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.25, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.64 in one year’s time.
Technical Analysis of Nuvation Bio Inc (NUVB)
Looking closely at Nuvation Bio Inc (NYSE: NUVB), its last 5-days average volume was 3.37 million, which is a jump from its year-to-date volume of 2.8 million. As of the previous 9 days, the stock’s Stochastic %D was 77.16%. Additionally, its Average True Range was 0.17.
During the past 100 days, Nuvation Bio Inc’s (NUVB) raw stochastic average was set at 22.45%, which indicates a significant decrease from 79.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 95.08% in the past 14 days, which was higher than the 74.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0064, while its 200-day Moving Average is $2.5856. However, in the short run, Nuvation Bio Inc’s stock first resistance to watch stands at $2.0183. Second resistance stands at $2.0667. The third major resistance level sits at $2.1333. If the price goes on to break the first support level at $1.9033, it is likely to go to the next support level at $1.8367. Now, if the price goes above the second support level, the third support stands at $1.7883.
Nuvation Bio Inc (NYSE: NUVB) Key Stats
The company with the Market Capitalisation of 669.15 million has total of 338,679K Shares Outstanding. Its annual sales at the moment are 7,870 K in contrast with the sum of -567,940 K annual income. Company’s last quarter sales were recorded 5,710 K and last quarter income was -49,450 K.
